ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double

  • ADMA Biologics Inc ADMA achieved Q3 sales of $20.7 million, + 101% Y/Y, beating the consensus of $18.72 million.
  • The increase was favorably impacted by the continued commercial ramp-up of ADMA's intravenous immune globulin (IVIG) product portfolio and the sale of intermediate fractions.
  • The company generated a gross profit of $0.4 million compared to a gross loss of $(1.6) million a year ago, primarily attributable to increased sales of ADMA's higher-margin hyperimmune globulin product portfolio, along with a portion of the sales generated from conformance batches.
  • Q3 consolidated net loss reached $(17.7) million, compared to $(16.9) million last year. EPS loss was $(0.13) compared to $(0.19) a year ago, better than the consensus of $(0.14).
  • ADMA had cash and equivalents of $34.4 million and accounts receivable of $20.4 million as of September 30, 2021. On October 25, 2021, the company raised $53.9 million through a public offering.
  • Price Action: ADMA shares are up 10.7% at $1.55 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!